Aimery de Gramont on Muck Rack

Aimery de Gramont

As seen in: Nature, Therapeutic Advances in Medical Oncology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Aimery

Contact Aimery, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

STRATEGIC-1: multiple-line, randomized, open-label GERCOR-PRODIGE-39 phase III trial in unresectable RAS/BRAF wild-type metastatic colorectal cancer

|
By Benoist Chibaudel, Thierry Andre, Thierry André, Julie Henriques, Vincent Bourgeois, Jérôme Desrame, Elisabeth Carola, Olivier Dupuis, Nabil Baba-Hamed, Dominique Auby, Christophe Louvet, Emmanuel Maillard, Olivier Romano, Christophe Tournigand, Einat Shacham-Shmueli, Brian Bird, Francois Ghiringhelli, Aimery de Gramont, Louis-Marie Dourthe, Pierre-Luc Etienne, Marie-Line Garcia-Larnicol
| Nature Verified
Abstract Managing unresectable metastatic colorectal cancer (mCRC) requires a comprehensive strategy. While chemotherapy, anti-angiogenic, and anti-epidermal growth factor receptor (EGFR) agents are available, strategy trials are needed to optimize their use and sequencing. The STRATEGIC-1 phase III trial (NCT01910610) was designed to determine the optimal treatment sequence in patients with untreated, unresectable wild-type RAS/BRAFV600E mCRC.
Open in Who Shared Issue with article?
|
By Thierry André, Mark Saunders, Wojciech Rogowski, Ron N. Apte, Prasant Mohanty, John Simard, Aimery de Gramont, Tamas Hickish, Lucjan Wyrwicz, Tomasz Sarosiek, Judit Kocsis, Radim Nemecek, Krzysztof Lesniewski-Kmak, Lubos Petruzelka, Michael Stecher
| secure.jbs.elsevierhealth.com
Open in Who Shared Issue with article?

Therapeutic strategy in unresectable metastatic colorectal cancer

|
By Benoist Chibaudel, Christophe Tournigand, Thierry André, Aimery de Gramont
| Therapeutic Advances in Medical Oncology Verified
While surgery is the cornerstone treatment for early-stage colorectal cancer, chemotherapy is the first treatment option for metastatic disease when tumor lesions are frequently not fully resectable at presentation. Mortality from colon cancer has decreased over the past 30 years, but there is still a huge heterogeneity in survival rates that can be mainly explained by patient and tumor characteristics, host response factors, and treatment modalities.
Open in Who Shared Issue with article?
See all 3 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified